Last reviewed · How we verify
MK0928 Phase II Sleep Laboratory Study - Primary Insomnia
A study to evaluate the efficacy, safety and tolerability of MK-0928 in Primary Insomnia.
Details
| Lead sponsor | H. Lundbeck A/S |
|---|---|
| Phase | Phase 2 |
| Status | TERMINATED |
| Enrolment | 50 |
| Start date | 2005-11 |
Conditions
- Primary Insomnia
Interventions
- MK0928, gaboxadol / Duration of Treatment: 6 days for treatment periods (2 days/dose)
- Placebo / Duration of Treatment: 2 days for screening period
Primary outcomes
- Mean of total sleep time over 2 nights.